ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 139

Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE

Aline Kühl Torricelli1, Michelle Remião Ugolini-Lopes 1, Eloisa Bonfa 2 and Danieli Andrade 3, 1Rheumatology Division - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, 3Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Antiphospholipid syndrome and systemic lupus erythematosus (SLE), Damage Index for APS

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombophilia that affects young productive individuals with permanent damage and negative impact in quality of life. Recently a damage index specific for APS (DIAPS) was developed. There are, however, no data regarding the comparison of its performance and long-term damage in primary antiphospholipid syndrome (PAPS) and APS related to SLE (APS+SLE). The primary purpose of this study was, therefore, to compare the long-term damage in patients with these conditions.

Methods: This is a retrospective analysis of a single tertiary center cohort followed for approximately 10 years, using a standardized prospective electronic chart database. Fifty consecutive PAPS patients age matched with fifty APS+SLE patients were consecutively selected for the study and DIAPS was calculated once-a-year during follow-up. Long term damage and damage kinetics in both groups were compared.

Results: PAPS and APS+SLE had comparable age (47.10±12.4 vs. 44.04±10.80 years, p=0.19) and time of follow-up (9.40±3.60 vs. 10.94±4.50 years, p=0.06).  At diagnosis, PAPS group had higher DIAPS than APS+SLE (1.72±1.17 vs. 0.82±0.96, p< 0.001). At the end of 10 years follow-up both groups presented comparable mean damage scores (2.04±1.50 vs. 2.24±1.61, p=0.52). The damage increment throughout the observation period for PAPS was solely 35% whereas for APS+SLE it was gradual, persistent and reached 139% at the end of follow up with a total damage increment for PAPS lower than APS+SLE group (0.43±0.30 vs. 1.22±1.24, p< 0.001). Of note, the frequency of individuals that acquired damage was lower in PAPS than in APS+SLE group (32% vs. 71%, p< 0.001). PAPS had also longer delay in diagnosis than APS+SLE (4.00±4.20 vs. 2.54±3.05 years, p=0.04). This delay was positively correlated to a higher damage score at diagnosis (r=0.36, p< 0.001) in all groups.

Conclusion: We identified a distinct pattern of damage in PAPS and APS related to SLE. Damage in PAPS is an early event  while APS+SLE is associated with higher long term damage with a striking increment of damage along the follow-up. Diagnosis delay is correlated with higher damage scores. Damage surveillance requires therefore different approaches for these two conditions.

Table 1. Demographic features and damage scores in PAPS and APS related to SLE patients

Table 2 Comparison of damage domains at the end of follow-up of PAPS and APS+SLE

Figure 1. Cumulative incidence of damage along follow-up in PAPS and APS related to SLE


Disclosure: A. Kühl Torricelli, None; M. Remião Ugolini-Lopes, None; E. Bonfa, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #305068/2014-8), 2, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4 and #2010/10749-0), 2; D. Andrade, None.

To cite this abstract in AMA style:

Kühl Torricelli A, Remião Ugolini-Lopes M, Bonfa E, Andrade D. Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/antiphospholipid-syndrome-damage-index-diaps-distinct-long-term-kinetic-in-primary-antiphospholipid-syndrome-and-aps-related-to-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphospholipid-syndrome-damage-index-diaps-distinct-long-term-kinetic-in-primary-antiphospholipid-syndrome-and-aps-related-to-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology